{"url_path":"/sec/cik-0001697884/10-k/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","accession_number":"0001640334-26-001082","cik":"0001697884","ticker":null,"issuer_name":"VITASPRING BIOMEDICAL CO. LTD.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1697884/0001640334-26-001082-index.html","primary_entity_key":"0001697884","primary_entity_name":"VITASPRING BIOMEDICAL CO. LTD."},"word_count":1391,"has_tables":true,"body_markdown":"vsbc_10k.htm\n0001697884false--01-31FY20260false0.0001500000000207030030207030030207030030falsefalsefalsefalse24110000P0YP0Y00000016978842025-02-012026-01-310001697884vsbc:AdditionsMember2025-02-012026-01-310001697884vsbc:ChengHsiangKaoMember2025-02-012026-01-310001697884vsbc:ChengHsiangKaoMember2024-02-012025-01-310001697884vsbc:VehicleMember2025-02-012026-01-310001697884us-gaap:EquipmentMembervsbc:TopMember2025-02-012026-01-310001697884us-gaap:EquipmentMembervsbc:BottomMember2025-02-012026-01-310001697884us-gaap:SubsequentEventMember2026-05-180001697884us-gaap:ComputerEquipmentMember2026-01-310001697884us-gaap:ComputerEquipmentMember2025-01-310001697884us-gaap:OtherMachineryAndEquipmentMember2026-01-310001697884us-gaap:OtherMachineryAndEquipmentMember2025-01-310001697884us-gaap:VehiclesMember2026-01-310001697884us-gaap:VehiclesMember2025-01-310001697884us-gaap:RetainedEarningsMember2026-01-310001697884us-gaap:AdditionalPaidInCapitalMember2026-01-310001697884us-gaap:CommonStockMember2026-01-310001697884us-gaap:RetainedEarningsMember2025-02-012026-01-310001697884us-gaap:AdditionalPaidInCapitalMember2025-02-012026-01-310001697884us-gaap:CommonStockMember2025-02-012026-01-310001697884us-gaap:RetainedEarningsMember2025-01-310001697884us-gaap:AdditionalPaidInCapitalMember2025-01-310001697884us-gaap:CommonStockMember2025-01-310001697884us-gaap:RetainedEarningsMember2024-02-012025-01-310001697884us-gaap:AdditionalPaidInCapitalMember2024-02-012025-01-310001697884us-gaap:CommonStockMember2024-02-012025-01-3100016978842024-01-310001697884us-gaap:RetainedEarningsMember2024-01-310001697884us-gaap:AdditionalPaidInCapitalMember2024-01-310001697884us-gaap:CommonStockMember2024-01-3100016978842024-02-012025-01-3100016978842025-01-3100016978842026-01-3100016978842026-06-1700016978842025-07-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**FORM 10-K**\n\n \n\n☒\n\n**ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the fiscal year ended **January 31, 2026**\n\n \n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nCommission File No. **333-216645**\n\n \n\n**VITASPRING BIOMEDICAL CO., LTD.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n\n**37-1836726**\n\nState or other jurisdiction of Incorporation or organization\n\n(IRS Employer Identification No.)\n\n \n\n**5225 Canyon Crest Drive, Suite 71-825, Riverside, CA**\n\n**92507**\n\n(Address of principal executive offices)\n\n(Zip Code)\n\n \n\nRegistrant’s telephone number, including area code **(949) 202-9235**\n\n Securities registered pursuant to Section 12(b) of the Act: None\n\n \n\nTitle of each class\n\n \n\nTrading Symbol(s)\n\n \n\nName of each exchange on which registered\n\nNone\n\n \n\nN/A\n\n \n\nN/A \n\n \n\nSecurities registered pursuant to Section 12(g) of the Act: None\n\n \n\n**None**\n\n(Title of class) \n\n \n\n**None**\n\n(Title of class) \n\n \n\nIndicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐     No ☒\n\n \n\nIndicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐     No ☒\n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐     No ☒\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\n \n\nEmerging growth company\n\n☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes ☐     No ☒\n\n \n\nIndicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐\n\n \n\nIf securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ☐ Yes     ☒ No\n\n \n\nState the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter. As of July 31, 2025, the aggregate market value of the registrant’s voting and non-voting common stock equity held by non-affiliates could not be reliably determined because the common stock was thinly traded and there was limited publicly available information regarding non-affiliate holdings. There were 154,730,010 shares held by non-affiliates as of that date.\n\n \n\nAs of June 17, 2026, the registrant had 207,030,030 shares of common stock issued and outstanding.\n\n \n\n \n\n \n\n \n\n**TABLE OF CONTENTS**\n\n \n\n \n\n**PART I**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 1](#i1)\n\n[BUSINESS](#i1)\n\n \n\n4\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 1A](#i1a)\n\n[RISK FACTORS](#i1a)\n\n \n\n10\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 1B](#i1b)\n\n[UNRESOLVED STAFF COMMENTS](#i1b)\n\n \n\n15\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 1C](#i1c)\n\n[CYBERSECURITY](#i1c)\n\n \n\n15\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 2](#i2)\n\n[PROPERTIES](#i2)\n\n \n\n16\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 3](#i3)\n\n[LEGAL PROCEEDINGS](#i3)\n\n \n\n16\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 4](#i4)\n\n[MINE SAFETY DISCLOSURES](#i4)\n\n \n\n16\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**PART II**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 5](#i5)\n\n[MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS, AND ISSUER PURCHASES OF EQUITY SECURITIES](#i5)\n\n \n\n17\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 6](#i6)\n\n[RESERVED](#i6)\n\n \n\n18\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 7](#i7)\n\n[MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](#i7)\n\n \n\n18\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 7A](#i7a)\n\n[QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](#i7a)\n\n \n\n23\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 8](#i8)\n\n[FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA](#i8)\n\n \n\n24\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 9](#i9)\n\n[CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE](#i9)\n\n \n\n25\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 9A](#i9a)\n\n[CONTROLS AND PROCEDURES](#i9a)\n\n \n\n25\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 9B](#i9b)\n\n[OTHER INFORMATION](#i9b)\n\n \n\n25\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 9C](#i9c)\n\n[DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS](#i9c)\n\n \n\n25\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**PART III**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 10](#i10)\n\n[DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS; COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT](#i10)\n\n \n\n26\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 11](#i11)\n\n[EXECUTIVE COMPENSATION](#i11)\n\n \n\n29\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 12](#i12)\n\n[SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS](#i12)\n\n \n\n30\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 13](#i13)\n\n[CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE](#i13)\n\n \n\n30\n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 14](#i14)\n\n[PRINCIPAL ACCOUNTANT FEES AND SERVICES](#i14)\n\n \n\n31\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n**PART IV**\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[ITEM 15](#i15)\n\n[EXHIBITS AND FINANCIAL STATEMENT SCHEDULES](#i15)\n\n \n\n32\n\n \n\n \n\n \n\n2\n\n*Table of Contents*\n\n  \n\n**SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Annual Report on Form 10-K for the fiscal year ended January 31, 2026 (this “Report”) is being filed after its original due date. We are working to regain full compliance with our periodic reporting obligations under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Except as otherwise indicated, all information contained in this Report is presented as of January 31, 2026.\n\n \n\nThis Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Exchange Act. These statements relate to our expectations, beliefs, plans, objectives, intentions, and assumptions regarding future events or performance and are not statements of historical fact. Words such as *“may,” “will,” “could,” “should,” “expect,” “believe,” “estimate,” “anticipate,” “intend,” “plan,” “continue,” “potential,”*and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.\n\n \n\nThese statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions, and are subject to known and unknown risks, uncertainties, and factors that could cause actual results to differ materially from those expressed or implied. Important factors that could cause such differences include, but are not limited to:\n\n \n\n \n\n·\n\nour ability to develop, commercialize, and market our functional-medicine and nutraceutical formulations;\n\n \n\n·\n\nour dependence on third-party research, manufacturing, and supply partners;\n\n \n\n·\n\nour ability to raise additional capital to fund operations;\n\n \n\n·\n\ncompetition within the biomedical and nutraceutical industries;\n\n \n\n·\n\nloss of key personnel or inability to attract qualified employees and consultants;\n\n \n\n·\n\nregulatory approvals, compliance costs, and potential changes in applicable laws;\n\n \n\n·\n\ndisruptions in supply chains or research partnerships;\n\n \n\n·\n\neconomic, geopolitical, and market conditions;\n\n \n\n·\n\ninadequacy of insurance coverage for certain losses or liabilities; and\n\n \n\n·\n\npotential asset impairments or other non-cash charges.\n\n \n\nForward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Readers should not place undue reliance on these statements, which speak only as of the date of this Report. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events, new information, or the occurrence of unanticipated events.\n\n \n\nAs used in this Report, unless otherwise indicated, the terms “VitaSpring Biomedical,” “VitaSpring,” “we,” “us,” “our,” or the “Company” refer to *VitaSpring Biomedical Co. Ltd.*All dollar amounts are expressed in U.S. dollars unless otherwise specified.\n\n \n\nReaders are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.\n\n \n\n \n\n3\n\n*Table of Contents*\n\n \n\n**PART I**"}